A player in the bustling microbiome R&D arena promotes its CSO to the top post -- just ahead of a PhII NASH study
There’s been a change of leadership — and strategy — at one of the Bay Area biotechs looking to play a prominent role in microbiome R&D.
Glenn Nedwin is out as CEO of Second Genome, leaving the top post open for chief scientific officer Karim Dabbagh to step into. Also out is the broad-based approach to R&D that Nedwin had, including ag work, as the biotech looks to create a razor-sharp focus on an upcoming Phase II for NASH — a blockbuster target which has inspired a frenzy of competition.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.